LATEST NEWS

OUR PIPELINE

our pipeline - type texture hero

A new standard in radiation oncology

Through our lead product NBTXR3, we aim to help millions of patients fighting cancer worldwide by improving treatment outcomes without increasing harmful side effects. We believe that radiotherapy-activated NBTXR3 has the potential to become the global standard of care in the treatment of solid tumors.

NBTXR3 in the clinic

Indication
Trial Name
Approach
Phase I
Phase II
Phase III
Head and Neck Locally Advanced
NANORAY-312
NBTXR3-RT* ± cetuximab
Study 102
NBTXR3-RT*
Phase I
Phase II
Phase III
Head and Neck Recurrent And/Or Metastatic
TBD Planning
NBTXR3-RT* + anti-PD-1
Phase I
Phase II
Phase III
Study 1100
NBTXR3-RT* + anti-PD-1
Phase I
Phase II
Phase III
Completed Studies
nanobiotix logo

Demonstrated safety, feasibility, and clinical activity of NBTXR3-RT* across multiple solid tumors

Soft Tissue Sarcoma
NBTXR3-RT*
Rectal**
NBTXR3-RT* + Chemo Tx
Head and Neck**
NBTXR3-RT* + Chemo Tx
Liver
NBTXR3-RT*
Ongoing Studies
MD Anderson Cancer Center - logo

Exploring safety, feasibility, and efficacy of NBTXR3-RT* in solid tumors

Head and Neck
NBTXR3-RT* + Anti-PD-1
Pancreatic
NBTXR3-RT* + Chemo Tx
Esophageal
NBTXR3-RT* + Chemo Tx
NSCLC
NBTXR3-RT*

*NBTXR3-RT: NBTXR3 activated by radiotherapy; **Study terminated prior to completion as result of conclusion of collaboration, results presented at ASCO 22

Clinical trials

Radiotherapy-activated NBTXR3 is currently being evaluated alone and in combination with other anticancer therapies in ongoing clinical trials that span an array of solid tumors. These trials evaluate the efficacy and safety of NBTXR3 in various cancer types and will provide important insights into the potential applications of it in clinical practice.

For inquiries about our technology, collaborations, clinical trials, or other topics, we encourage you to get in touch with our team.